Close

JPMorgan Starts ADC Therapeutics (ADCT) at Overweight

September 21, 2022 6:06 AM EDT Send to a Friend
JPMorgan analyst Brian Cheng initiates coverage on ADC Therapeutics (NYSE: ADCT) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login